Artivion Inc. reported fourth‑quarter 2025 results that included total revenue of $116.0 million, a 18% increase on an adjusted constant‑currency basis, but a slight miss of the consensus estimate of $117.25 million. Net income rose to $2.4 million, reversing a $16.5 million loss a year earlier, and GAAP earnings per share climbed to $0.05 from a loss of $0.39. The company also disclosed a non‑GAAP diluted EPS of $0.17, beating the consensus estimate of $0.14 by $0.03, or 21%.
Revenue growth was driven by strong demand for the company’s high‑margin medical device portfolio. Stent graft sales increased 44% year‑over‑year, while On‑X mechanical valve sales grew 25%. The preservation services segment posted 6% growth, reflecting the resolution of a cybersecurity incident that had previously slowed tissue‑processing revenue. A $2.3 million Italian payback adjustment reduced reported revenue and gross margin, but the company’s mix shift toward higher‑margin products helped maintain a 63% gross margin in Q4 2025, the same as the prior year.
Operating profitability expanded as adjusted EBITDA rose to $22.7 million, up 29% from $17.6 million in Q4 2024. The adjusted EBITDA margin increased to 19.2% from 17.5% a year earlier, driven by cost controls and the higher mix of high‑margin devices. The company’s gross margin remained flat at 63%, but the Italian payback adjustment and manufacturing inefficiencies offset some of the margin expansion, illustrating the company’s ability to preserve profitability amid regulatory and operational headwinds.
Management reiterated its 2026 outlook, projecting full‑year revenue of $486 million to $504 million and adjusted EBITDA of $105 million to $110 million. The guidance reflects confidence in continued market penetration of the AMDS aortic arch device and the ongoing conversion of bioprosthetic valve patients to the On‑X line. The company’s pipeline, including the AMDS PERSEVERE and NEXUS TRIOMPHE trials, is expected to sustain double‑digit revenue growth and margin expansion in the coming years.
Market reaction to the results was mixed. Investors weighed the strong non‑GAAP EPS beat and margin expansion against the revenue miss, which led to a slight decline in after‑hours trading. Analysts noted that the EPS surprise was a key driver of positive sentiment, while the revenue shortfall tempered enthusiasm.
"We are very pleased with our strong performance for the full year 2025," said CEO Pat Mackin. "We drove 13% adjusted constant‑currency revenue growth and 26% adjusted EBITDA growth, while making substantial progress in advancing our aortic‑focused product development pipeline." CFO Lance Berry added, "Total adjusted revenues were $118.3 million for the fourth quarter of 2025, excluding the Italian payback adjustment, up 18.5% compared to Q4 of 2024."
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.